Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...
A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...
A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
19h
Cencora simplifies distribution logistics by shipping products to centralized wholesaler locations, as opposed to shipping directly to pharmacies and various customer locations. Additionally, Cencora ...
A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback